Search research articles
Contact Us
Filters
Showing results (101-110 of 170) with videos related to
Page
of 17
Sort By:
The New Zealand Medical Journal
|
October 28, 2008
Netilmicin withdrawal: impact on neonates
Catherine M T Sherwin, Sofia Svahn, Roland S Broadbent, et al.
Frontiers in Pharmacology
|
February 13, 2023
Current use of complementary and conventional medicine for treatment of pediatric patients with gastrointestinal disorders
Casey L Sayre, Venkata Kashyap Yellepeddi, Kathleen M Job, et al.
Pediatric Pulmonology
|
September 6, 2012
Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: IV. colistimethate sodium
David C Young, Jeffery T Zobell, C Dustin Waters, et al.
Clinical Pharmacokinetics
|
May 30, 2014
Pharmacokinetics and pharmacodynamics of antibacterials, antifungals, and antivirals used most frequently in neonates and infants
Jessica K Roberts, Chris Stockmann, Jonathan E Constance, et al.
Clinical Pharmacokinetics
|
May 21, 2015
Population Pharmacokinetics of Darbepoetin Alfa in Conjunction with Hypothermia for the Treatment of Neonatal Hypoxic-Ischemic Encephalopathy
Jessica K Roberts, Chris Stockmann, Robert M Ward, et al.
The AAPS Journal
|
May 30, 2019
Population Pharmacokinetic Modeling in the Presence of Missing Time-Dependent Covariates: Impact of Body Weight on Pharmacokinetics of Paracetamol in Neonates
Wojciech Krzyzanski, Sarah F Cook, Melanie Wilbaux, et al.
Pediatric Pulmonology
|
September 6, 2012
Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: II. cephalosporins and penicillins
Jeffery T Zobell, C Dustin Waters, David C Young, et al.
Pediatric Pulmonology
|
August 23, 2012
Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: I. aztreonam and carbapenems
Jeffery T Zobell, David C Young, C Dustin Waters, et al.
Pediatric Pulmonology
|
January 30, 2013
Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: VI. Executive summary
Jeffery T Zobell, David C Young, C Dustin Waters, et al.
Pediatric Pulmonology
|
September 4, 2013
Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: V. Aminoglycosides
David C Young, Jeffery T Zobell, Chris Stockmann, et al.
Page
of 17
Search research articles
Search
Showing results (101-110 of 170) with videos related to
Sort By:
Page
of 17
The New Zealand Medical Journal
|
October 28, 2008
Netilmicin withdrawal: impact on neonates
Catherine M T Sherwin, Sofia Svahn, Roland S Broadbent, et al.
Frontiers in Pharmacology
|
February 13, 2023
Current use of complementary and conventional medicine for treatment of pediatric patients with gastrointestinal disorders
Casey L Sayre, Venkata Kashyap Yellepeddi, Kathleen M Job, et al.
Pediatric Pulmonology
|
September 6, 2012
Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: IV. colistimethate sodium
David C Young, Jeffery T Zobell, C Dustin Waters, et al.
Clinical Pharmacokinetics
|
May 30, 2014
Pharmacokinetics and pharmacodynamics of antibacterials, antifungals, and antivirals used most frequently in neonates and infants
Jessica K Roberts, Chris Stockmann, Jonathan E Constance, et al.
Clinical Pharmacokinetics
|
May 21, 2015
Population Pharmacokinetics of Darbepoetin Alfa in Conjunction with Hypothermia for the Treatment of Neonatal Hypoxic-Ischemic Encephalopathy
Jessica K Roberts, Chris Stockmann, Robert M Ward, et al.
The AAPS Journal
|
May 30, 2019
Population Pharmacokinetic Modeling in the Presence of Missing Time-Dependent Covariates: Impact of Body Weight on Pharmacokinetics of Paracetamol in Neonates
Wojciech Krzyzanski, Sarah F Cook, Melanie Wilbaux, et al.
Pediatric Pulmonology
|
September 6, 2012
Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: II. cephalosporins and penicillins
Jeffery T Zobell, C Dustin Waters, David C Young, et al.
Pediatric Pulmonology
|
August 23, 2012
Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: I. aztreonam and carbapenems
Jeffery T Zobell, David C Young, C Dustin Waters, et al.
Pediatric Pulmonology
|
January 30, 2013
Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: VI. Executive summary
Jeffery T Zobell, David C Young, C Dustin Waters, et al.
Pediatric Pulmonology
|
September 4, 2013
Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: V. Aminoglycosides
David C Young, Jeffery T Zobell, Chris Stockmann, et al.
Page
of 17